HealthQuest participates in follow-on financing for Venus Concept

HealthQuest participates in follow-on financing for Venus Concept

HealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested an additional $7 million in Venus Concept concurrent with the completion of the acquisition of NeoGraft.  NeoGraft is an industry leader in the area of hair restoration technologies.  Venus Concept's industry first and only subscription-based business model, combined with its global reach in over 60 countries and 27 direct global offices, will create a significant opportunity to expand the overall combined businesses of both NeoGraft and Venus Concept.

HealthQuest leads $20 million investment into Springbuk

HealthQuest leads $20 million investment into Springbuk

HealthQuest led a $20 million investment into Springbuk, the leading employer-facing health intelligence software.  HealthQuest was joined in this investment by Echo Health Ventures and Lewis & Clark Ventures.

Springbuk was founded in 2015 by Rod Reasen and Phil Daniels, co-founders of the Healthiest Employers awards program, with the mission to empower employers to lower their healthcare costs by harnessing their health data. Today, over 1,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.

Castle Biosciences Launches Next-Generation Sequencing Panel for Uveal Melanoma

Castle Biosciences Launches Next-Generation Sequencing Panel for Uveal Melanoma

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.

HealthQuest Participates in $38M Financing for Venus Concept

HealthQuest Participates in $38M Financing for Venus Concept

HealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested $38M into innovative aesthetics technology company Venus Concept. Venus Concept uses a unique subscription-based hardware business model and innovative technologies to partner with aesthetic physicians around the world for body shaping and skin rejuvenation.Thousands of satisfied patients and customers are using Venus technologies every day in over 50 countries worldwide.  Our award-winning technology strives to make a profound impact in the aesthetic communities we serve around the world.

Read more

Garheng Kong selected for Aspen Institute's Health Innovators Fellowship

Garheng Kong selected for Aspen Institute's Health Innovators Fellowship

HealthQuest Capital Managing Partner, Dr. Garheng Kong, was selected as one of 21 healthcare industry leaders to participate in the Aspen Insitute's Health Innovators Fellowship. He and the other fellows will participate in a two-year Fellowship designed to strengthen the leadership of innovators across the US health care ecosystem and challenge them to create new approaches to improve the health and well-being of all Americans.

 

HQC portfolio company Spirox acquired by Entellus

HQC portfolio company Spirox acquired by Entellus

Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that it has entered into a definitive agreement to acquire Spirox, Inc., a privately-held ENT medical technology company that develops, manufactures and markets the LATERA™ Absorbable Nasal Implant, a minimally invasive option for ENTs and facial plastic surgeons to treat nasal airway obstruction. 

Trice Medical Closes $19.3 Million Series C Financing

Trice Medical Closes $19.3 Million Series C Financing

Trice Medical announced today that it closed a $19.3 million Series C financing and will use the proceeds to accelerate and expand the company's U.S. market penetration for mi-eye2™, R&D, sales, marketing and key international regulatory approvals. Smith & Nephew (LSE:SN, NYSE: SNN) has taken a minority stake joining a consortium of current investors including HealthQuest.

HealthQuest's Garheng Kong named among "12 VC's That Matter But You Never Read About" by the Timmerman Report

HealthQuest's Garheng Kong named among "12 VC's That Matter But You Never Read About" by the Timmerman Report

The Timmerman Report, an independent publication focused on in-depth reporting in the biotech and medical technology space, recently named HealthQuest Managing Partner Garheng Kong in a profile article titled "12 VC's That Matter, But You Never Read About". The article quotes one CEO as saying "I've never met anyone as well-liked and connected as he is. Garheng taps those connections to help his portfolio companies and those far down the line, is always the smartest guy in the room, but doesn't have to remind you of that, seems to be way ahead of his peers in identifying trends."

HealthQuest Joins Syndicate for $42M Investment in Avedro

HealthQuest Joins Syndicate for $42M Investment in Avedro

Avedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with strong support from existing investors OrbiMed Advisors and InterWest Partners. 

Blue Cross/Blue Shield Issues Positive Assessment of Castle Bioscience Test

Blue Cross/Blue Shield Issues Positive Assessment of Castle Bioscience Test

Friendswood, TX – March 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Blue Cross Blue Shield Association Evidence Street™ has issued a positive assessment of DecisionDx®-UM, the Company’s gene expression profile (GEP) test to determine prognosis (metastatic potential) in patients diagnosed with uveal melanoma (UM). Evidence Street provides objective information to healthcare and managed care professionals based on clinical and scientific evidence and evaluates whether a technology could improve net health outcomes

Trice Medical's Mi-Eye Featured in Businessweek

Trice Medical's Mi-Eye Featured in Businessweek

Bloomberg Businessweek columnist Michael Belfiore featured Trice's Mi-Eye device as a key innovation to watch (see here: https://www.bloomberg.com/news/articles/2017-02-16/this-needle-cam-can-diagnose-joint-injuries-without-an-mri ). The Mi-Eye allows doctor's to immediately diagnose knee injuries by direct visualization via an "optical needle", thereby eliminating the trip to the MRI.

Vestagen protects Healthcare workers in NYC with Northwell Health

Vestagen protects Healthcare workers in NYC with Northwell Health

Vestagen Protective Technologies has begun supplying uniforms to Northwell Health, the largest hospital system in New York, with 60,000 healthcare workers. News outlets in New York City have given great coverage, including this from NY1 TV: http://www.ny1.com/nyc/all-boroughs/health-and-medicine/2017/02/22/germ-resistant-scrubs-gaining-traction-in-city-hospitals.html

HealthQuest joins Vesey Street in recapitalization of HealthChannels (ScribeAmerica)

HealthQuest joins Vesey Street in recapitalization of HealthChannels (ScribeAmerica)

Vesey Street Capital Partners, LLC (VSCP) today announced the completed recapitalization of HealthChannels (parent company of ScribeAmerica), a healthcare services organization with a full suite of solutions that enhances provider productivity, streamlines clerical processes and improves health outcomes. With 13,000 employees across 50 states and three countries, HealthChannels is uniquely positioned to help providers meet increased demands around mission-critical activities ranging from electronic medical records documentation to patient navigation, medical billing and coding. HealthQuest Capital and Heritage Group joined Vesey Street in the financing.

HealthQuest Leads Investment in Avizia

HealthQuest Leads Investment in Avizia

Avizia, the leading end to end telehealth solution provider, today announced the completion of its Series A financing totaling $17 million. The company raised an additional $6 million to supplement the initial $11 million, which was announced in July 2016. HealthQuest Capital led the additional round which included investment from strategic partner NewYork-Presbyterian. 

Trice Medical Receives FDA Clearance for MiEye2

Trice Medical Receives FDA Clearance for MiEye2

Trice Medical announced today that it received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for mi-eye 2, a disposable needle with a fully integrated camera that enables physicians to use advanced diagnostic imaging to visualize joint injuries in their clinic. 

HealthQuest leads $13.8M into Magnolia Medical

HealthQuest leads $13.8M into Magnolia Medical

Magnolia Medical Technologies, developer of the SteriPath® blood collection system and leader in improving the quality and accuracy of in-vitro diagnostic test results, today announced the closing of the company's $13.8 million Series B financing led by HealthQuest Capital. In conjunction with the financing, Garheng Kong, M.D., Ph.D., founder and managing partner of HealthQuest Capital will join the company's board.

Virmedica Expands Senior Management Team

Virmedica Expands Senior Management Team

VirMedica, the leader in providing e-access and specialty pharmacy technology solutions designed to expedite patient access to biopharmaceutical products, today announced the appointment of three new executives to the Company's senior leadership team. John J. Arcari has been appointed to chief financial officer (CFO) and will oversee the Company's financial operations. Richard Deyermond joins the company as vice president of client services and will lead teams engaged in the delivery of VirMedica's technology solutions. As the vice president of engineering, Elizabeth Ricci will focus on building out the Company's technology suite.

Virmedica Appoints Phil Lee as CEO

Virmedica Appoints Phil Lee as CEO

VirMedica, the leader in providing eACCESS technology solutions designed to expedite patient access to biopharmaceutical products, today announced that its Board of Directors has appointed Philip Lee as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately.

William A. Hawkins III Joins Trice Medical's Board of Directors

William A. Hawkins III Joins Trice Medical's Board of Directors

Trice Medical, an early stage medical device company, announced the appointment of William Hawkins to the company's board of directors, effective April 1, 2016. Hawkins joins a distinguished Board of proven industry leaders in their pursuit to revolutionize arthroscopic diagnostics. Mr. Hawkins is a renowned healthcare executive with diverse experience in healthcare delivery, innovation, and entrepreneurship.